Stock listing
NYSE American:OGEN Oragenics Inc. Stock
Home listing (NYSE American) of Oragenics Inc.
Follow Oragenics Inc. into a list and get an email when it puts out news.
Share price · AMEX:OGEN
$0.157 USD -0.032 (-16.9%)
Close on Nov 20, 2026
- Day range
- $0.157 – $0.176 USDNov 20, 2026
- Volume
- 323,075 sharesNov 20, 2026
- Market cap
- $708,377 USDAt the close on Nov 20, 2026 · price × 4.51M shares outstanding
- 52-week range
- $0.157 – $1.110 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $242,246 USDMedian day 22,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:OGEN · Home | $0.157 USD | -0.032 (-16.9%) | 323,075 | $0.176 | $0.176 | $0.157 | $0.189 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:OGEN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.157 | -0.032 | -16.9% | $0.176 | $0.176 | $0.157 | 323,075 | |
| $0.189 | -0.021 | -10.0% | $0.204 | $0.208 | $0.181 | 326,785 | |
| $0.210 | +0.012 | +6.1% | $0.183 | $0.213 | $0.183 | 665,480 | |
| $0.198 | -0.002 | -1.0% | $0.181 | $0.201 | $0.181 | 1,875,147 | |
| $0.200 | -0.150 | -42.9% | $0.210 | $0.230 | $0.170 | 16,410,000 | |
| $0.350 | +0.010 | +2.9% | $0.340 | $0.380 | $0.340 | 31,772,200 | |
| $0.340 | 0.000 | 0.0% | $0.350 | $0.350 | $0.340 | 2,000 | |
| $0.340 | -0.010 | -2.9% | $0.370 | $0.370 | $0.340 | 10,000 | |
| $0.350 | 0.000 | 0.0% | $0.400 | $0.400 | $0.340 | 15,700 | |
| $0.350 | 0.000 | 0.0% | $0.350 | $0.350 | $0.350 | 8,900 | |
| $0.350 | -0.020 | -5.4% | $0.370 | $0.370 | $0.340 | 48,300 | |
| $0.370 | 0.000 | 0.0% | $0.370 | $0.380 | $0.370 | 3,700 | |
| $0.370 | 0.000 | 0.0% | $0.380 | $0.390 | $0.370 | 8,400 | |
| $0.370 | 0.000 | 0.0% | $0.420 | $0.420 | $0.370 | 47,800 | |
| $0.370 | 0.000 | 0.0% | $0.370 | $0.390 | $0.370 | 9,200 | |
| $0.370 | -0.010 | -2.6% | $0.380 | $0.380 | $0.370 | 6,300 | |
| $0.380 | +0.010 | +2.7% | $0.380 | $0.400 | $0.370 | 13,800 | |
| $0.370 | -0.030 | -7.5% | $0.400 | $0.400 | $0.350 | 62,400 | |
| $0.400 | -0.020 | -4.8% | $0.420 | $0.420 | $0.400 | 17,300 | |
| $0.420 | +0.010 | +2.4% | $0.410 | $0.420 | $0.400 | 9,400 | |
| $0.410 | 0.000 | 0.0% | $0.410 | $0.410 | $0.400 | 20,400 | |
| $0.410 | -0.020 | -4.7% | $0.440 | $0.440 | $0.410 | 5,300 | |
| $0.430 | +0.010 | +2.4% | $0.440 | $0.450 | $0.410 | 14,800 | |
| $0.420 | -0.010 | -2.3% | $0.440 | $0.450 | $0.420 | 36,000 | |
| $0.430 | -0.010 | -2.3% | $0.450 | $0.450 | $0.430 | 32,700 | |
| $0.440 | 0.000 | 0.0% | $0.430 | $0.460 | $0.430 | 11,600 | |
| $0.440 | -0.010 | -2.2% | $0.450 | $0.450 | $0.430 | 16,900 | |
| $0.450 | 0.000 | 0.0% | $0.450 | $0.450 | $0.440 | 16,300 | |
| $0.450 | -0.010 | -2.2% | $0.460 | $0.460 | $0.450 | 17,200 | |
| $0.460 | 0.000 | 0.0% | $0.470 | $0.480 | $0.450 | 28,200 | |
| $0.460 | -0.040 | -8.0% | $0.500 | $0.500 | $0.460 | 45,800 | |
| $0.500 | +0.010 | +2.0% | $0.500 | $0.500 | $0.490 | 11,600 | |
| $0.490 | 0.000 | 0.0% | $0.490 | $0.490 | $0.480 | 12,300 | |
| $0.490 | 0.000 | 0.0% | $0.480 | $0.500 | $0.480 | 42,300 | |
| $0.490 | +0.010 | +2.1% | $0.480 | $0.500 | $0.480 | 15,400 | |
| $0.480 | -0.010 | -2.0% | $0.490 | $0.520 | $0.480 | 32,400 | |
| $0.490 | +0.010 | +2.1% | $0.480 | $0.500 | $0.470 | 14,400 | |
| $0.480 | +0.010 | +2.1% | $0.490 | $0.490 | $0.460 | 42,000 | |
| $0.470 | -0.020 | -4.1% | $0.510 | $0.510 | $0.460 | 33,300 | |
| $0.490 | -0.010 | -2.0% | $0.520 | $0.520 | $0.480 | 11,800 | |
| $0.500 | +0.010 | +2.0% | $0.490 | $0.500 | $0.490 | 17,400 | |
| $0.490 | -0.030 | -5.8% | $0.520 | $0.530 | $0.490 | 40,000 | |
| $0.520 | 0.000 | 0.0% | $0.520 | $0.530 | $0.500 | 25,300 | |
| $0.520 | +0.040 | +8.3% | $0.480 | $0.520 | $0.480 | 37,900 | |
| $0.480 | -0.040 | -7.7% | $0.500 | $0.520 | $0.480 | 43,000 | |
| $0.520 | +0.020 | +4.0% | $0.500 | $0.520 | $0.490 | 48,900 | |
| $0.500 | +0.010 | +2.0% | $0.500 | $0.520 | $0.480 | 54,500 | |
| $0.490 | -0.010 | -2.0% | $0.490 | $0.500 | $0.480 | 25,200 | |
| $0.500 | +0.020 | +4.2% | $0.480 | $0.500 | $0.480 | 23,500 | |
| $0.480 | -0.020 | -4.0% | $0.500 | $0.500 | $0.480 | 66,900 | |
| $0.500 | -0.020 | -3.8% | $0.510 | $0.510 | $0.500 | 9,200 | |
| $0.520 | 0.000 | 0.0% | $0.520 | $0.520 | $0.510 | 4,700 | |
| $0.520 | +0.010 | +2.0% | $0.510 | $0.520 | $0.510 | 12,600 | |
| $0.510 | +0.010 | +2.0% | $0.500 | $0.520 | $0.500 | 8,300 | |
| $0.500 | -0.010 | -2.0% | $0.510 | $0.520 | $0.500 | 22,900 | |
| $0.510 | +0.010 | +2.0% | $0.510 | $0.530 | $0.500 | 25,300 | |
| $0.500 | -0.010 | -2.0% | $0.500 | $0.520 | $0.500 | 16,100 | |
| $0.510 | -0.010 | -1.9% | $0.520 | $0.530 | $0.490 | 101,200 | |
| $0.520 | -0.010 | -1.9% | $0.530 | $0.530 | $0.520 | 73,800 | |
| $0.530 | 0.000 | 0.0% | $0.530 | $0.540 | $0.510 | 29,600 | |
| $0.530 | +0.010 | +1.9% | $0.540 | $0.540 | $0.520 | 7,200 | |
| $0.520 | 0.000 | 0.0% | $0.510 | $0.530 | $0.510 | 12,900 | |
| $0.520 | -0.010 | -1.9% | $0.520 | $0.530 | $0.510 | 30,400 | |
| $0.530 | -0.010 | -1.9% | $0.530 | $0.540 | $0.520 | 56,400 | |
| $0.540 | +0.010 | +1.9% | $0.550 | $0.550 | $0.530 | 16,000 |
Splits
4 splits since 2010 · AMEX:OGEN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation | |
| 1-for-60 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-20 | Consolidation |
- Ticker
- NYSE American:OGEN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Oragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028
Latest deck · Sep 16, 2026
IPAC-RS Successful Studies Case (September 2026)
Conference · 21 slides
Latest news
Oragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028
Nov 12, 2026
Closed $0.20 (-42.9%) on Nov 13, 2026
Investor Presentation - May 2026
May 19, 2026
Closed $0.57 (0.0%) on May 19, 2026
Oragenics provides investor update
May 18, 2026
Closed $0.57 (-3.4%) on May 18, 2026
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
May 7, 2026
Closed $0.61 (-1.6%) on May 7, 2026
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
May 5, 2026
Closed $0.64 (+3.2%) on May 5, 2026
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Apr 20, 2026
Closed $0.71 (-1.4%) on Apr 20, 2026
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Mar 25, 2026
Closed $0.58 (-6.5%) on Mar 26, 2026
Oragenics files annual report on Form 10-K
Mar 17, 2026
Closed $0.78 (-2.5%) on Mar 17, 2026
Oragenics initiates Phase IIa clinical trial site activation
Mar 12, 2026
Closed $0.96 (+9.1%) on Mar 12, 2026
Oragenics explores expansion of CNS platform pursuing acquistion of assets in brain health, recovery, and neuroprotection
Mar 11, 2026
Closed $0.88 (-10.2%) on Mar 11, 2026
Oragenics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 30 in all · newest Nov 12, 2026 · oldest 2025
- Decks
- 28 decks · latest Sep 16, 2026
Where Oragenics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:OGEN · Home listing · This page | NYSE American | United States | USD |
| BOATS:OGEN | BOATS | United States | USD |
| gettex:UAV0 | gettex | Germany | EUR |
| LSE:0A64 | LSE | United Kingdom | USD |
| Munich:UAV0 | Munich | Germany | EUR |
Valuation
Price/book 0.7× against a median of 0.2×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$1.12M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.4×
- Beta vs S&P 500
- 1.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Oragenics Inc. · AMEX:OGEN | US$708,377 | −US$1.12M | n/a | n/a | n/a | 0.7× | n/a | 0.4× | 1.47 |
| Valion Bio, Inc. · NASDAQ:VBIO | US$1.04M | US$16.34M | n/a | 42.8× | n/a | 0.2× | n/a | 4.1× | 1.11 |
| GeoVax Labs, Inc. · NASDAQ:GOVX | US$985,460 | −US$915,033 | n/a | n/a | n/a | 0.9× | n/a | 0.2× | 1.47 |
| Biodexa Pharmaceuticals plc · NASDAQ:BDRX | US$982,950 | −US$3.22M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.01 |
| Gabather AB · OMXSTO:GABA | US$919,514 | US$559,105 | n/a | n/a | n/a | 6.4× | n/a | 0.0× | n/a |
| ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2 | US$792,634 | −US$2.43M | n/a | −6.5× | n/a | 0.2× | −935.9% | 0.0× | n/a |
| Silexion Therapeutics Corp · NASDAQ:SLXN | US$790,001 | −US$3.60M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 2.77 |
| Protagenic Therapeutics, Inc. · OTC:PTIX | US$687,879 | US$610,970 | 0.1× | n/a | n/a | 0.6× | n/a | 0.0× | 1.21 |
| Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABT | US$580,337 | −US$2.74M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.46 |
| Mushrooms, Inc. · OTC:MSRM | US$539,339 | US$564,177 | n/a | n/a | n/a | n/a | n/a | n/a | 1.24 |
| Jaguar Health, Inc. · NASDAQ:JAGX | US$527,406 | −US$1.48M | n/a | −0.1× | n/a | 0.0× | −181.8% | 0.2× | 3.75 |
| Median of the others | US$791,318 | −US$1.20M | 0.1× | −0.1× | 0.2× | −558.9% | 0.0× | 1.23 |
Forecasts
1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.00 USD · Analysts' mean
- EPS, year to Dec 2025
- -0.76 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Janet Huffman | Chief Executive Officer & Chief Financial Officer |
| Frederick W. Telling | Executive Chairman |
| James P. Kelly | Chief Medical Officer |
| William Frank Peacock | Chief Clinical Officer |
Board
| Director | Role |
|---|---|
| Charles L. Pope | Chairman of the Board |
| Frederick W. Telling | Executive Chairman |
| Alan Dunton | Director |
| John Gandolfo | Director |
| Natasha Giordano | Board Member |
| Robert Koski | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 | −41.2% |
| Q2 2026 | Aug 13, 2026 | −1.9% |
| Q1 2026 | May 8, 2026 | −8.2% |
| Q3 2025 | Nov 7, 2025 | 0.0% |
| Q2 2025 | Aug 8, 2025 | −10.0% |
| Q1 2025 | May 9, 2025 | 0.0% |
| Q4 2024 | Mar 27, 2025 · After close | −4.3% |
| Q3 2024 | Nov 7, 2024 · After close | +21.9% |
| Q2 2024 | Aug 9, 2024 · After close | +48.6% |
| Q1 2024 | May 15, 2024 · After close | 0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 29, 2024 · After close | −0.7% |
| Q3 2023 | Nov 9, 2023 · After close | −4.0% |
| Q2 2023 | Aug 11, 2023 · After close | +0.6% |
| Q1 2023 | May 12, 2023 · After close | −0.3% |
| Q4 2022 | Mar 27, 2023 · After close | +12.6% |
| Q3 2022 | Nov 14, 2022 · After close | +4.8% |
| Q2 2022 | Aug 9, 2022 · After close | 0.0% |
| Q1 2022 | May 13, 2022 · After close | −3.7% |
| Q4 2021 | Mar 24, 2022 · After close | −10.5% |
| Quarter to Sep 30, 2021 | Nov 15, 2021 · After close | −3.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IPAC-RS Successful Studies Case (September 2026) | Conference | 21 slides | Sep 16, 2026 |
| Investor Presentation (May 2026) | Investor deck | 15 slides | May 2026 |
| Investor Presentation (January 2026) | Investor deck | 17 slides | Jan 20, 2026 |
| Corporate Update (May 2025) | Corporate update | 28 slides | May 20, 2025 |
| Investor Presentation (October 2024) | Investor deck | 16 slides | Oct 16, 2024 |
| Investor Presentation (November 2023) | Investor deck | 8 slides | Nov 20, 2023 |
| Investor Presentation (April 2023) | Investor deck | 14 slides | Apr 3, 2023 |
| Investor Presentation (October 2022) | Investor deck | 14 slides | Oct 3, 2022 |
| Investor Presentation (April 2022) | Investor deck | 11 slides | Apr 19, 2022 |
| Investor Presentation (November 2021) | Investor deck | 21 slides | Nov 12, 2021 |
All 28 decks
Financings
| Raise | Date |
|---|---|
| Public offering of series H Convertible Preferred Stock and Warrants Closed: US$16.5M raised · US$25 a share · 1 warrant at US$25 for 60 months · Dawson James Securities, Inc. Dealers: Dawson James Securities, Inc. (lead) Use of proceeds: Clinical development of ONP-002, other R&D, repay a $3 million bridge note, working capital and general corporate purposes | Jul 2, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 37.7K | 131.5K | 87.0K | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 4.11M | 15.5M | 44.7K | 41.2K | 22.1M | 62.6K | 30.1K | 0 | 0 | |
| Gross profit | -4.11M | -27.4K | 86.9K | 45.8K | -22.1M | -62.6K | -30.1K | 0 | 0 | |
| Research and development | 2.39M | 4.11M | 15.5M | 10.1M | 10.6M | 22.1M | 12.1M | 5.97M | 3.54M | 4.75M |
| Selling, general and administrative | 6.97M | 6.44M | 5.45M | 4.48M | 5.27M | 4.53M | 3.76M | 4.02M | 3.18M | 3.79M |
| Operating income | -9.36M | -10.6M | -20.9M | -14.4M | -15.8M | -26.6M | -15.9M | -9.99M | -6.72M | -8.54M |
| Depreciation and amortization | 771.4M | 0 | 27.4K | 44.7K | 41.2K | 51.7K | 62.6K | 30.1K | 65.8K | 75.0K |
| EBITDA | 762.1M | -10.6M | -20.9M | -14.4M | -15.7M | -26.6M | -15.8M | -9.96M | -6.65M | -8.47M |
| Interest expense | 785.9K | 29.8K | 30.6K | 15.1K | 15.8K | 10.7K | 7.30K | 5.79K | 216.3K | 4.12K |
| Income before tax | -9.98M | -10.6M | -20.7M | -14.3M | -15.7M | -26.4M | -15.6M | -9.91M | -6.73M | -8.50M |
| Income tax | -136.9K | -1 | -127.0K | 16.4K | 12.5K | 7.76K | 0 | 0 | 0 | |
| Net income | -9.84M | -10.6M | -20.7M | -14.3M | -15.7M | -26.4M | -15.6M | -9.91M | -6.73M | -7.01M |
| Earnings per share, basic | -4.56 | -47.88 | -9.18 | -7.11 | -8.09 | -0.47 | -0.37 | -0.87 | -1.37 | -1.57 |
| Earnings per share, diluted | -4.56 | -47.88 | -9.18 | -7.11 | -0.14 | -0.47 | -0.37 | -0.87 | -1.37 | -1.57 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.40M | 864.8K | 3.48M | 11.4M | 27.3M | 17.6M | 18.3M | 20.2M | 6.17M | 4.08M |
| Short-term investments | 4.00M | 0 | 17.9K | 0 | 0 | |||||
| Receivables | 53.1K | 6.99K | 6.99K | 0 | ||||||
| Inventory | 0 | 0 | ||||||||
| Current assets | 10.1M | 1.47M | 3.87M | 14.3M | 27.7M | 18.0M | 18.8M | 21.9M | 7.19M | 4.22M |
| Property, plant and equipment | 0 | 121.1K | 45.7K | 42.7K | 92.0K | 116.3K | 21.7K | 87.5K | ||
| Goodwill | 0 | 0 | ||||||||
| Total assets | 10.1M | 1.47M | 4.97M | 14.8M | 28.2M | 18.7M | 19.8M | 22.0M | 7.21M | 4.31M |
| Accounts payable | 1.56M | 1.14M | 1.24M | 246.7K | 855.0K | 330.4K | 1.21M | 828.7K | 618.4K | 461.3K |
| Current liabilities | 1.79M | 1.68M | 1.80M | 1.60M | 1.45M | 1.34M | 1.85M | 1.17M | 898.5K | 1.34M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 227.3K | 328.5K | 322.5K | 624.5K | 797.2K | 898.9K | 979.6K | 124.2K | 80.5K | 66.4K |
| Total liabilities | 1.79M | 1.68M | 1.80M | 1.75M | 1.74M | 1.84M | 2.52M | 1.17M | 898.5K | 1.34M |
| Shareholders' equity | 8.28M | -211.9K | 3.17M | 13.0M | 26.5M | 16.8M | 17.2M | 20.9M | 6.32M | 2.97M |
| Shares outstanding | 4.27M | 419.0K | 3.08M | 2.02M | 2.00M | 91.8M | 46.1M | 29.4M | 4.93M | 4.91M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.25M | -8.60M | -7.29M | -15.2M | -13.5M | -17.0M | -13.0M | -9.08M | -6.36M | -7.08M |
| Capital spending | -3 | 0 | -1.00M | -127.5K | -43.9K | -43.9K | -25.2K | -124.7K | -124.7K | -27.2K |
| Free cash flow | -9.25M | -8.60M | -8.29M | -15.4M | -13.5M | -17.0M | -13.0M | -9.20M | -6.36M | -7.10M |
| Cash from investing | -936.3K | -115.5K | -43.9K | -43.9K | -25.2K | -124.7K | -124.7K | 1.68M | ||
| Cash from financing | 16.8M | 5.98M | 283.9K | -494.9K | 23.1M | 16.3M | 11.1M | 23.2M | 8.45M | 4.45M |
| Dividends paid | -1.12M | -1.12M | -661.5K | -413.2K | -58.7K | 0 | 0 | |||
| Share buybacks | -5.64M | -5.64M | 661.5K | 252.9K | 58.7K | 6.18M | 2.64M | |||
| Change in cash | 7.53M | -2.62M | -7.94M | -15.8M | 9.63M | -628.4K | -1.94M | 14.0M | 2.09M | -948.6K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Sep 16, 2026 | Current report | SEC |
| 8-K · Current report | Aug 28, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 6, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | May 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 19, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PRE 14A · Preliminary proxy statement | May 8, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Current report | SEC |
| 8-K · Current report | Apr 13, 2026 | Current report | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 23, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 19, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Mar 19, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2026 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jan 27, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 22, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 22, 2026 | Material contract | SEC |
| 4/A · Change in ownership, amended | Jan 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 21, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 2, 2025 | Management or board change | SEC |
| 3 · Initial statement of ownership | Sep 2, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 26, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 11, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 2, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 2, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jul 2, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 1, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 30, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 26, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 26, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 23, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jun 23, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jun 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jun 2, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Jun 2, 2025 | Offer document | SEC |
| 8-K · Current report | May 28, 2025 | Current report | SEC |
| 8-K · Current report | May 20, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 2, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Apr 28, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 11, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Apr 11, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 10, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 9, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 1, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 27, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 19, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Mar 14, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2025 | Current report | SEC |
| 8-K · Current report | Feb 18, 2025 | Current report | SEC |
| 8-K · Current report | Feb 5, 2025 | Current report | SEC |
| RW · Request to withdraw a registration | Feb 4, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| 8-K · Current report | Jan 17, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jan 17, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 14, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 8, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Dec 31, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 31, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 30, 2024 | Other filings | SEC |
| S-1 · Registration statement | Dec 19, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Dec 16, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 6, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 6, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 29, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Oct 31, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 31, 2024 | Meeting notice | SEC |
| 8-K · Current report | Oct 18, 2024 | Current report | SEC |
| 8-K · Current report | Oct 16, 2024 | Current report | SEC |
| 8-K · Current report | Oct 11, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Oct 11, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 20, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Sep 11, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 5, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Sep 5, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 4, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 3, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 3, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 23, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 21, 2024 | Current report | SEC |
| S-1 · Registration statement | Aug 16, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 16, 2024 | Current report | SEC |
| 8-K · Current report | Aug 14, 2024 | Current report | SEC |
| 8-K · Current report | Aug 12, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Current report | SEC |
| 8-K · Current report | Jul 22, 2024 | Current report | SEC |
| 8-K · Current report | Jul 10, 2024 | Current report | SEC |
| 8-K · Current report | Jun 26, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 25, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Jun 24, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 20, 2024 | Current report | SEC |
| 8-K · Current report | May 23, 2024 | Current report | SEC |
| 8-K · Current report | May 22, 2024 | Current report | SEC |
| 8-K · Current report | May 17, 2024 | Current report | SEC |
| 8-K · Current report | May 16, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Current report | SEC |
| 8-K · Current report | Apr 19, 2024 | Current report | SEC |
| 8-K · Current report | Apr 15, 2024 | Current report | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Mar 6, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Mar 1, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Feb 29, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 28, 2024 | Current report | SEC |
| 8-K · Current report | Feb 27, 2024 | Current report | SEC |
| FWP · Free writing prospectus | Feb 27, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Feb 27, 2024 | Offer document | SEC |
| SC 13D · Big-stake notice | Feb 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 7, 2024 | Current report | SEC |
| 8-K · Current report | Feb 5, 2024 | Current report | SEC |
| 8-K · Current report | Jan 23, 2024 | Current report | SEC |
| 5 · Annual statement of ownership | Jan 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 16, 2024 | Current report | SEC |
| FWP · Free writing prospectus | Jan 16, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Jan 16, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jan 10, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2024 | Current report | SEC |
| 8-K · Current report | Dec 29, 2023 | Acquisition or disposal | SEC |
| 8-K · Current report | Dec 15, 2023 | Management or board change | SEC |
| 8-K · Current report | Dec 8, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 1, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 30, 2023 | Other filings | SEC |
| 8-K · Current report | Nov 20, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | Nov 16, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | Nov 2, 2023 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Oct 30, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 30, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 6, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Oct 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 5, 2023 | Management or board change | SEC |
| 8-K · Current report | Oct 5, 2023 | Material contract | SEC |
| 8-K · Current report | Sep 29, 2023 | Current report | SEC |
| 8-K · Current report | Sep 15, 2023 | Current report | SEC |
| 8-K · Current report | Aug 18, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 10, 2023 | Management or board change | SEC |
| D | Aug 7, 2023 | Other filings | SEC |
| 8-K · Current report | Aug 7, 2023 | Material contract | SEC |
| 8-K · Current report | Jun 5, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| 10-K · Annual report | Apr 17, 2023 | Annual report | SEC |
| 10-Q/A · Quarterly report, amended | Apr 14, 2023 | Quarterly report | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Oragenics Inc.’s releases · as of Nov 11, 2026
- Common shares
- 4,511,957
- Fully diluted
- 5,171,957
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 4,511,957 | Nov 11, 2026 |
| Warrants | 660,000 | Jul 2, 2025 |
Warrants and options
| Lot |
|---|
| Warrants · US$25.00 · expire about Jul 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 4,511,957 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kimberly M Murphy Other companies: Onconetix, Inc. (Director · Feb 17, 2022 – May 4, 2022 · Past); Clarus Therapeutics Holdings Inc (Director · Dec 12, 2021 – Jun 7, 2022 · Past); Blue Water Acquisition Corp (Director · Dec 14, 2020 – Dec 14, 2020 · Past) | Director · May 1, 2020 – Sep 19, 2024 · Past |
| John P. Gandolfo Other companies: electroCore, Inc. (Audit Committee Member, Compensation Committee Member · Since at least Jun 13, 2024); Hyperion DeFi, Inc. (Chief Financial Officer · Feb 12, 2024 – Feb 12, 2024 · Past) | Director · Since at least Oct 4, 2023 |
| Natasha Giordano Other companies: Matinas BioPharma Holdings, Inc. (Director · Nov 1, 2021 – Nov 1, 2023 · Past); PLx Pharma Inc (Chief Executive Officer, Director · Nov 18, 2020 – Mar 15, 2022 · Past) | Director · Since at least Sep 1, 2025 |
| Frederick W. Telling Other companies: CTi Biopharma Corp (Director · Nov 11, 2011 – Sep 18, 2018 · Past) | Executive Chairman · Since at least Nov 14, 2011 |
| Janet Huffman Other companies: Scienture Holdings, Inc. (CFO, PAO, PFO · Apr 2, 2022 – Dec 13, 2022 · Past) | Chief Executive Officer & Chief Financial Officer · Since at least Mar 7, 2023 |
| J. Michael Redmond Other companies: Odyssey Health Inc. (Chairman of the Board · Since at least Nov 28, 2018) | President · Dec 28, 2023 – Sep 19, 2024 · Past |
| Robert Koski Other companies: Helios Technologies, Inc. (Director · Jun 30, 2016 – Jul 12, 2016 · Past) | Director · Since at least Sep 17, 2013 |
| Alan Dunton | Director · Since at least Nov 5, 2026 |
| Charles L. Pope | Chairman of the Board · Since at least May 19, 2026 |
| James P. Kelly | Chief Medical Officer · Since at least May 19, 2026 |
All 13 people
| Person | Seat |
|---|---|
| John Spencer | Chief Financial Officer · Since at least Jul 1, 2026 |
| Michael O'Keefe Sullivan | Chief Financial Officer · Feb 5, 2020 – Jul 29, 2022 · Past |
| William Frank Peacock | Chief Clinical Officer · Since at least May 19, 2026 |
Log in to ask 6ix AI your own questions about Oragenics Inc.